

## NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

### Proposed Single Technology Appraisal (STA)

**Aflibercept in combination with irinotecan and fluorouracil-based therapy for the treatment of metastatic colorectal cancer which has progressed following prior oxaliplatin-based chemotherapy**

#### Provisional matrix of consultees and commentators (pre-referral)

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> <li>• sanofi aventis and Regeneron Pharmaceuticals (aflibercept)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Afiya Trust</li> <li>• Beating Bowel Cancer</li> <li>• Black Health Agency</li> <li>• Bladder &amp; Bowel Foundation</li> <li>• Bowel Cancer UK</li> <li>• CANCERactive</li> <li>• Cancer Black Care</li> <li>• Cancer Equality</li> <li>• Colostomy Association</li> <li>• Counsel and Care</li> <li>• Equalities National Council</li> <li>• Helen Rollason Heal Cancer Charity</li> <li>• IA: Ileostomy and Internal Pouch Support Group</li> <li>• Lynn's Bowel Cancer Campaign</li> <li>• Macmillan Cancer Support</li> <li>• Maggie's Centres</li> <li>• Marie Curie Cancer Care</li> <li>• Muslim Council of Britain</li> <li>• Muslim Health Network</li> <li>• Ostomy Lifestyle Centre</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Sue Ryder Care</li> <li>• Tenovus</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of Cancer Physicians</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Commissioning Support Appraisals Service</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Alliance</li> <li>• NHS Commercial Medicines Unit</li> <li>• NHS Confederation</li> <li>• Public Health Wales NHS Trust</li> <li>• Scottish Medicines Consortium</li> </ul> <p><u>Possible comparator manufacturer(s)</u></p> <ul style="list-style-type: none"> <li>• Actavis UK (irinotecan)</li> <li>• Goldshield (fluorouracil)</li> <li>• Hospira UK (calcium folinate, irinotecan, fluorouracil)</li> <li>• Medac UK (irinotecan, fluorouracil)</li> <li>• Merck Serono (tegafur with uracil)</li> <li>• Mylan (calcium folinate, irinotecan)</li> <li>• Pfizer (irinotecan, calcium folinate, calcium levofolinate)</li> <li>• Roche (capecitabine)</li> <li>• Sandoz (irinotecan, calcium folinate, fluorouracil)</li> </ul>

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• Association of Coloproctology of Great Britain</li> <li>• Association of Surgeons of Great Britain and Ireland</li> <li>• British Association for Services to the Elderly</li> <li>• British Association of Surgical Oncology</li> <li>• British Geriatrics Society</li> <li>• British Institute for Radiology</li> <li>• British Psychosocial Oncology Society (BPOS)</li> <li>• British Society of Gastroenterology</li> <li>• Cancer Network Pharmacists Forum</li> <li>• Cancer Research UK</li> <li>• Pelican Cancer Foundation</li> <li>• Royal College of Anaesthetists</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal College of Radiologists</li> <li>• Royal College of Surgeons</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• Society and College of Radiographers</li> <li>• United Kingdom Clinical Pharmacy Association</li> <li>• United Kingdom Oncology Nursing Society</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health</li> <li>• NHS Lambeth</li> <li>• NHS North Yorkshire and York</li> <li>• Welsh Government</li> </ul>	<ul style="list-style-type: none"> <li>• Teva UK (irinotecan, calcium folinate)</li> <li>• Wockhardt UK (calcium folinate, fluorouracil)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Bowel &amp; Cancer Research</li> <li>• Cochrane Colorectal Cancer Group</li> <li>• CORE – The Digestive Disorders Foundation</li> <li>• Institute of Cancer Research</li> <li>• MRC Clinical Trials Unit</li> <li>• National Cancer Research Institute</li> <li>• National Cancer Research Network</li> <li>• National Institute for Health Research</li> <li>• Research Institute for the Care of Older People</li> </ul> <p><u>Evidence Review Group</u></p> <ul style="list-style-type: none"> <li>• Evidence Review Group tbc</li> <li>• National Institute for Health Research Health Technology Assessment Programme</li> </ul> <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> <li>• National Collaborating Centre for Cancer</li> </ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• tbc</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected

characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

***PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS***

**Definitions:**

National Institute for Health and Clinical Excellence  
Provisional matrix for the proposed technology appraisal of aflibercept in combination with irinotecan and fluorouracil-based therapy for the treatment of metastatic colorectal cancer which has progressed following prior oxaliplatin-based chemotherapy  
Issue date: September 2011

### Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland ; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*).

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

### Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

---

<sup>1</sup> Non manufacturer consultees are invited to submit statements relevant to the group they are representing.